New $250M Atlas fund to target later-stage investments

Atlas Venture closed its oversubscribed Atlas Venture Opportunity Fund I at $250 million, intended to support growth for Akero Therapeutics Inc. (South San Francisco, Calif.) and other existing portfolio companies.

Atlas told BioCentury the fund surpassed its $200 million target and reached its hard cap...